Background PTP4A3 is a subclass of a protein tyrosine phosphatase super family and is expressed in a range of epithelial neoplasms. We evaluated PTP4A3 expression and its association with clinicopathological parameters in different types of functioning pituitary adenomas.
Methods A total of 34 functioning pituitary adenomas samples were evaluated in this observational study. PTP4A3 expression was examined by immunohistochemical staining, and, possible correlations between PTP4A3 and some clinicopathological variables were investigated.
Results PTP4A3 was expressed in 19 out of 34 tumours (55%), at the cytoplasmic level of tumorous cells. Moreover, there was significant association (p=0.042) between PTP4A3 expression and tumorous size.
Conclusions PTP4A3 was expressed in more than half of the tumours analysed, with there being a significant association with the tumorous size of functioning adenomas. This allows to speculate that PTP4A3 may regulate tumour growth, although further investigations are necessary to determine if this phosphatase can serve as a biomarker or used as a therapeutic target in pituitary macroadenomas.
- microscopy, electron
- pituitary diseases
Statistics from Altmetric.com
Handling editor Runjan Chetty.
Contributors All authors contributed to the design of the study, writing or critical review of the manuscript, analysis and interpretation of data. All agreed to submission of the manuscript.
Funding This work was supported by La Agencia Nacional de Promoción Científica y Tecnológica, Fondo Nacional de Ciencia y Tecnología (ANPCyT-FONCYT-PICT 2014-2555), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET- PIP-Res #154/2014) and Secretaria de Ciencia y Tecnología de la Universidad Nacional de Cordoba (SECyT–UNC Res # 313/2016).
Competing interests None declared.
Patient consent for publication Obtained.
Ethics approval CIEIS del Hospital Córdoba (Registro Nacional de Investigaciones en Salud Nº CO000152 (RENIS)).
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.